Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the phenylpyrazole class. It was developed as a potent and water-soluble inhibitor of the mitotic kinesin spindle protein KIF11 (also known as Eg5 or kinesin-like protein KSP), which is essential for establishing bipolar spindles during cell division. Inhibition of KIF11 leads to mitotic arrest with monoastral microtubule arrays and prevents centrosome migration. The compound was designed using structure-based drug design strategies to improve potency and solubility over earlier inhibitors. Its primary research focus has been in oncology as an anti-mitotic agent targeting cancer cell proliferation[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5S)-5-(3-aminopropyl)-3-(2,5-difluorophenyl)-N-ethyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide.